Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robyn Wolintz

Neurology Brooklyn, NY Medical Doctor

NPI 1497760888 CMS profile 249055

883 65Th St, Brooklyn, NY 11219

Open in the dashboard

General payments

$46,648

572 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robyn Wolintz of Brooklyn, NY is reported in the CMS Open Payments database as having received $46,648 across 572 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,047 67
2024 General $1,639 57
2023 General $2,312 83
2022 General $2,173 109
2021 General $1,879 93
2020 General $11,185 47
2019 General $25,413 116

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robyn Wolintz
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Robyn Wolintz were reported at $2,047. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Robyn Wolintz Neurology median Middle half National median
2019 $25,413 $474 $118–$2,177 $163
2020 $11,185 $367 $82–$2,309 $114
2021 $1,879 $438 $104–$2,547 $132
2022 $2,173 $442 $103–$2,388 $149
2023 $2,312 $464 $119–$2,312 $160
2024 $1,639 $468 $119–$2,323 $164
2025 $2,047 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $29,573 113 payments
  2. Genzyme Corporation $7,469 25 payments
  3. Novartis Pharmaceuticals Corporation $1,043 69 payments
  4. AbbVie, Inc. $868 41 payments
  5. Argenx US, Inc. $835 22 payments
  6. TG Therapeutics, Inc. $779 16 payments
  7. Celgene Corporation $705 39 payments
  8. Alexion Pharmaceuticals, Inc. $549 17 payments
  9. Allergan Inc. $471 26 payments
  10. E.R. Squibb & Sons, L.L.C. $454 11 payments
  11. Other $3,902 193 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,177 15 payments
  2. Food and Beverage $13,745 548 payments
  3. Consulting Fee $7,790 2 payments
  4. Travel and Lodging $840 5 payments
  5. Education $96 2 payments
Products named General payments · program years 2019–2025
  1. TYSABRI $18,013 70 payments
  2. TECFIDERA $17,179 27 payments
  3. AUBAGIO $7,217 11 payments
  4. ZEPOSIA $1,077 46 payments
  5. VUMERITY Neurology $1,066 30 payments
  6. BRIUMVI $779 16 payments
  7. UBRELVY $492 22 payments
  8. VYVGART Hytrulo $485 19 payments
  9. VUMERITY Neurology $442 13 payments
  10. BOTOX $387 29 payments
  11. Other $6,549 326 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

1,671

Median for Neurology: 833

Drug cost

$2,376,523

Median for Neurology: $202,670

Branded share of claims

38.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tecfidera Dimethyl Fumarate Brand 41 $440,542
Avonex Pen (4 Pack) Interferon Beta-1a Brand 25 $276,689
Copaxone Glatiramer Acetate Brand 38 $261,696
Aubagio Teriflunomide Brand 22 $232,818
Vumerity Diroximel Fumarate Brand 27 $230,695
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 19 $227,740
Gilenya Fingolimod Hcl Brand 14 $139,118
Betaseron Interferon Beta-1b Brand 13 $124,754
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 11 $105,157
Ampyra Dalfampridine Brand 14 $58,639

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$66,014

Medicare's payments for the services billed

Medicare patients

269

Average age 74

Services billed

3,361

181 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 54%
Ischemic heart disease 35%
Depression 28%
Osteoporosis 22%
COPD 19%
Chronic kidney disease 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYVGART Hytrulo
  • ARGENX US, INC. $307
$307 — —
ZEPOSIA
  • Celgene Corporation $137
  • E.R. Squibb & Sons, L.L.C. $125
$262 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $225
$225 — —
BRIUMVI
  • TG Therapeutics, Inc. $206
$206 — —
Leqembi
  • Biogen, Inc. $42
  • Eisai Inc. $28
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

572 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record